NACLC 23

Comprehensive and educational content from 2023 IASLC North America Conference on Lung Cancer (NACLC), taking place December 1-3, 2023, in Chicago, IL.

Patient, Caregiver Perceptions of the Burden of Chemotherapy-Induced Myelosuppression in Extensive-Stage SCLC

Mary GreccoSmall Cell Lung Cancer | March 26, 2024

Chemotherapy-induced myelosuppression among patients with extensive-stage SCLC is poorly understood.

Treatment Sequencing of Tepotinib in Patients With MET Exon 14 Skipping NSCLC: The VISION Study

Mary GreccoNon-Small Cell Lung Cancer | March 26, 2024

The VISION study that evaluated pre/post-tepotinib treatment in advanced/metastatic METex14 skipping NSCLC.

Comparing the Standard of Care With Tarlatamab in Relapsed Small Cell Lung Cancer: DeLLphi-304

Mary GreccoSmall Cell Lung Cancer | March 26, 2024

The DeLLphi-301 study that evaluated patients with advanced SCLC.

Impact of Reflexive, Comprehensive Versus Limited Next-Generation Sequencing on Time to Result and Time to Treatment in Advanced NSCLC

Mary GreccoNon-Small Cell Lung Cancer | March 25, 2024

Results of a study that evaluated the impact of comprehensive versus limited NGS for advanced NSCLC.

Treatment Patterns, Outcomes in Second-line Advanced NSCLC Treated After Prior Platinum Chemotherapy/IO Combination Therapy

Mary GreccoNon-Small Cell Lung Cancer | March 25, 2024

A study evaluated second-line treatment patterns and clinical outcomes of IO in NSCLC.

Outcomes After Progression With Anti-PD-L1, Chemotherapy in mNSCLC Clinical

Mary GreccoNon-Small Cell Lung Cancer | March 25, 2024

Patients with metastatic NSCLC who receive first-line anti-PD-L1-based IO may achieve durable disease control.

Lurbinectedin in Patients With SCLC: A Preliminary Safety Analysis From Jazz EMERGE 402

Mary GreccoSmall Cell Carcinoma | March 22, 2024

Lurbinectedin monotherapy is currently being studied in Jazz EMERGE 402 study in patients with metastatic SCLC.

Racial, Socioeconomic Disparities in Patients With NSCLC Treated With Immunotherapy

Mary GreccoNon-Small Cell Lung Cancer | March 21, 2024

Black and/or socioeconomically disadvantaged patients with advanced NSCLC have higher mortality rates.

Lung Cancer Screening at Appalachian VA Medical Center Versus the National Lung Screening Trial

Mary GreccoLung Cancer | March 21, 2024

Results of a lung screening program found a significantly higher lung cancer prevalence in veterans.

Characteristics, Outcomes Among Patients With Advanced NSCLC and HER2 Mutations

Mary GreccoNon-Small Cell Lung Cancer | March 20, 2024

A greater understanding of patients with HER2-mutated NSCLC is critical for developing therapies.